T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis

Ayumi Yoshifuji; Masataro Toda; Munekazu Ryuzaki; Emi Oyama; Kan Kikuchi; Toru Kawai; Ken Sakai; Masayoshi Koinuma; Kazuhiko Katayama; Takashi Yokoyama; Yuki Uehara; Norio Ohmagari; Yoshihiko Kanno; Hirofumi Kon; Toshio Shinoda; Yaoko Takano; Junko Tanaka; Kazuhiko Hora; Yasushi Nakazawa; Naoki Hasegawa; Norio Hanafusa; Fumihiko Hinoshita; Keita Morikane; Shu Wakino; Hidetomo Nakamoto; Yoshiaki Takemoto

doi:10.3390/vaccines11030653

Vaccines (Mar 2023)

T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis

Ayumi Yoshifuji,
Masataro Toda,
Munekazu Ryuzaki,
Emi Oyama,
Kan Kikuchi,
Toru Kawai,
Ken Sakai,
Masayoshi Koinuma,
Kazuhiko Katayama,
Takashi Yokoyama,
Yuki Uehara,
Norio Ohmagari,
Yoshihiko Kanno,
Hirofumi Kon,
Toshio Shinoda,
Yaoko Takano,
Junko Tanaka,
Kazuhiko Hora,
Yasushi Nakazawa,
Naoki Hasegawa,
Norio Hanafusa,
Fumihiko Hinoshita,
Keita Morikane,
Shu Wakino,
Hidetomo Nakamoto,
Yoshiaki Takemoto

Affiliations

Ayumi Yoshifuji: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Masataro Toda: Division of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan
Munekazu Ryuzaki: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Emi Oyama: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Kan Kikuchi: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Toru Kawai: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Ken Sakai: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Masayoshi Koinuma: Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo 164-8530, Japan
Kazuhiko Katayama: Laboratory of Viral Infection Control, Ōmura Satoshi Memorial Institute, Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan
Takashi Yokoyama: Department of Infectious Diseases, Keio University School of Medicine, Tokyo 160-8582, Japan
Yuki Uehara: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Norio Ohmagari: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Yoshihiko Kanno: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Hirofumi Kon: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Toshio Shinoda: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Yaoko Takano: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Junko Tanaka: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Kazuhiko Hora: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Yasushi Nakazawa: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Naoki Hasegawa: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Norio Hanafusa: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Fumihiko Hinoshita: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Keita Morikane: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Shu Wakino: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Hidetomo Nakamoto: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Yoshiaki Takemoto: Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan

DOI: https://doi.org/10.3390/vaccines11030653
Journal volume & issue: Vol. 11, no. 3
p. 653

Abstract

Read online

Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.

Published in Vaccines

ISSN: 2076-393X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine
Website: http://www.mdpi.com/journal/vaccines

About the journal

Abstract

Keywords